Breaking News

Tweet TWEET

FDA Reviews, Trial Initiation, New Innovations, and Multi-year Commercial Agreement - Research Report on Sanofi, Medivation,

  FDA Reviews, Trial Initiation, New Innovations, and Multi-year Commercial
  Agreement - Research Report on Sanofi, Medivation, Align Technology, WuXi
                           PharmaTech, and Insulet

PR Newswire

NEW YORK, December 16, 2013

NEW YORK, December 16, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Sanofi SA
(NYSE: SNY), Medivation, Inc. (NASDAQ: MDVN), Align Technology, Inc. (NASDAQ:
ALGN), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), and Insulet Corporation
(NASDAQ: PODD). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Sanofi SA Research Report

On December 11, 2013, Sanofi SA (Sanofi), along with its subsidiary Genzyme,
announced that the FDA has granted a six-month Priority Review designation to
Genzyme's NDA for Cerdelga (eliglustat), an investigational oral therapy for
adult patients with Gaucher disease type 1. The Company reported that Genzyme
is developing eliglustat and the clinical development for this drug is said to
be the largest clinical program ever conducted in Gaucher disease, with
approximately 400 patients treated in 29 countries. According to the Company,
FDA's Priority Review designation signifies that its goal is to take action on
the NDA within six months, compared to 10 months under standard review. The
Full Research Report on Sanofi SA - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/29ea_SNY

Medivation, Inc. Research Report

On December 4, 2013, Medivation, Inc. (Medivation) and Astellas Pharma US,
Inc. (Astellas) jointly announced the initiation of a Phase 2 clinical trial
evaluating the safety and efficacy of enzalutamide in combination with
exemestane in women with advanced breast cancer that is estrogen receptor
positive (ER+) or progesterone receptor positive (PgR+) and human epidermal
growth factor receptor 2 (HER2) normal. "Exemestane is a commonly used
aromatase inhibitor in patients whose tumors express either the estrogen or
progesterone receptor. It is our hope that inhibiting androgen receptor
signaling with enzalutamide in combination with exemestane will provide
benefit beyond the inhibition of estrogen and progesterone signaling in
patients with advanced breast cancer," said Lynn Seely, M.D., Chief Medical
Officer of Medivation. The Full Research Report on Medivation, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4277_MDVN

Align Technology, Inc. Research Report

On December 3, 2013, Align Technology, Inc. (Align Technology) announced the
upcoming release of Invisalign G5 innovations, specifically designed for the
treatment of deep bite malocclusions. "Invisalign G5 is our first set of
innovations designed to enhance treatment predictability for a specific type
of malocclusion," said John P. Graham, Vice President of Marketing and Chief
Marketing Officer of Align Technology. "Deep bite is a very prevalent,
functional problem that is important to correct, with an estimated 45 percent
of adult and teen patients presenting with this orthodontic problem. We're
pleased to introduce this set of innovative features that addresses such a big
part of our customers' practices and that will help drive increased
utilization of Invisalign over time." The Company expects Invisalign G5
innovations for deep bite to be available in Q1 2014. The Full Research Report
on Align Technology, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/69b3_ALGN

WuXi PharmaTech (Cayman) Inc. Research Report

On December 10, 2013, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech)
announced the winners of its seventh annual WuXi PharmaTech Life Science and
Chemistry Awards at a ceremony held on December 7, 2013, in Beijing. The
Company has presented the awards to 15 highly accomplished young scholars. The
Company reported that these awards originated in 2007 and aim to foster early
innovation and to encourage pursuit of excellence in life science research.
"We are excited to recognize some of the brightest minds in China through our
Life Science and Chemistry Awards," said Dr. Ge Li, Chairman and CEO of WuXi
PharmaTech. "Their excellent research has the potential to substantially help
our industry to better understand diseases and to find cures that benefit
patients around the world." The Full Research Report on WuXi PharmaTech
(Cayman) Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/df7b_WX

Insulet Corporation Research Report

On December 10, 2013, Insulet Corporation (Insulet) announced a five-year
commercial agreement with Amgen Inc. (Amgen), under which Insulet will supply
Amgen with a delivery device, built using its tubeless insulin pump
technology, which is specifically designed around the unique delivery needs of
biotechnology medicines. "Insulet's current device, the OmniPod®, is a unique
drug delivery platform that provides the ability to vary rate at which
medication is infused. With over 25 million OmniPods produced, our innovative
product is the undisputed global leader in patch pump technology and provides
a patient-friendly and cost effective drug delivery alternative," said Duane
DeSisto, President and CEO of Insulet. The Full Research Report on Insulet
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/75e4_PODD

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)